These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology]. van Herpen CM; de Mulder PH Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361 [TBL] [Abstract][Full Text] [Related]
24. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4. Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566 [TBL] [Abstract][Full Text] [Related]
26. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. Ramsey S; Aitchison M J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863 [No Abstract] [Full Text] [Related]
27. New drug therapies for advanced renal cell carcinoma. Gore ME; Harrison ML; Montes A Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520 [TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. Shaheen PE; Bukowski RM Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470 [TBL] [Abstract][Full Text] [Related]